Desteklenen Projeler
20
-
2024 - 2030 A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)
Diğer Ülkelerin Sanayi Kuruluşları Tarafından Desteklenmiş Proje
Yağcı A. M. (Yürütücü)
-
2023 - 2030 A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024 - 2029 SYMPHONY-1: A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
-
2024 - 2029 A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non- Hodgkin Lymphoma (OLYMPIA-4)
Diğer Ülkelerdeki Özel Organizasyonlar Tarafından Desteklenmiş Proje
Yağcı A. M. (Yürütücü)
-
2024 - 2029 BTK İnhibitörü ile önceden tedavi uygulanmış Kronik Lenfositik Lösemi /Küçük Lenfositik Lenfomada Araştırmacının Tercihine Göre İdelalisib ve Rutiksimab ya da Bendamustin ve Rutiksimab'a Kıyasla LOXO-305'in Değerlendirildiği Faz 3,Açık Etiketli,Randomiza Çalışma" başlıklı (BRUINCLL-321) protokol numaralı klinik
-
2023 - 2029 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody in Previously Untreated Participants with Follicular Lymphoma (FL) (OLYMPIA-2))
-
2023 - 2029 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Folliculr Lymphoma (FL) (OLYMPIA-1)
-
2023 - 2029 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
-
2023 - 2029 Nükseden mantle hücreli lenfomada bcl-2 inh sonrotoklaksın etkinliği
-
2023 - 2029 A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-
2022 - 2026 MOR208C310A Phase 3, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R- CHOP versus R-CHOP in high-intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma
-
2021 - 2026 A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
-
2019 - 2026 Nüks KML'li hastalarda Radotinibin etkinliği
-
2018 - 2026 The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
-
2024 - 2025 HEMATOLOJİK KANSERLERDE MOLEKÜLER TANI AMAÇLI REAL TİME PCR KİT GELİŞTİRİLMESİ
TÜBİTAK Projesi , 1501 - Sanayi Ar-Ge Projeleri Destekleme Programı
-
2023 - 2025 Polisitemi Vera Hastalarında Hepsidin Mimetik Rusfertidin (PTG-300) Faz 3 Çalışması"
-
2020 - 2025 A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versus in Combination with Acalabrutinib in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma / D8227C00001 / ACE-LY-312
-
2019 - 2025 A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemo immunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
-
2018 - 2025 A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (“Clinical Trial
-
2023 - 2024 Kronik Lenfositik Lösemi Hücrelerinde Dioscinin NLRP3 İnflamazomun İfadelenmesine ve Apoptoza Etkileri
Yükseköğretim Kurumları Destekli Proje , BAP Diğer
GÖKÇEN S. (Yürütücü), KAYHAN H., YAĞCI A. M., ÖZKURT Z. N., YEGİN Z. A.
